Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A OTT

Showing results (601-610 of 667) with videos related to

Pageof 67
Sort By:
Stapp Car Crash Journal|April 21, 2020
Kinematic and Biomechanical Response of Post-Mortem Human Subjects Under Various Pre-Impact Postures to High-Rate Vertical Loading ConditionsLauren Wood Zaseck, Anne C Bonifas, Carl S Miller, et al.
Journal for Immunotherapy of Cancer|March 8, 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumorsNikhil I Khushalani, Patrick A Ott, Robert L Ferris, et al.
Journal for Immunotherapy of Cancer|October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumorsOmid Hamid, Alberto A Chiappori, John A Thompson, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human studyAung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2019
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortNeal E Ready, Patrick A Ott, Matthew D Hellmann, et al.
Kidney International|June 11, 2016
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsFrank B Cortazar, Kristen A Marrone, Megan L Troxell, et al.
Cancer|April 23, 2020
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 studyJanice M Mehnert, Emily Bergsland, Bert H O'Neil, et al.
Clinical Epigenetics|July 30, 2015
Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomasJonathan J Lee, Lynette M Sholl, Neal I Lindeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell CarcinomaKent W Mouw, James M Cleary, Brendan Reardon, et al.
Cancer|January 29, 2019
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanomaPatrick A Ott, Anna C Pavlick, Douglas B Johnson, et al.
Pageof 67

Showing results (601-610 of 667) with videos related to

Sort By:
Pageof 67
Stapp Car Crash Journal|April 21, 2020
Kinematic and Biomechanical Response of Post-Mortem Human Subjects Under Various Pre-Impact Postures to High-Rate Vertical Loading ConditionsLauren Wood Zaseck, Anne C Bonifas, Carl S Miller, et al.
Journal for Immunotherapy of Cancer|March 8, 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumorsNikhil I Khushalani, Patrick A Ott, Robert L Ferris, et al.
Journal for Immunotherapy of Cancer|October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumorsOmid Hamid, Alberto A Chiappori, John A Thompson, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human studyAung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2019
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortNeal E Ready, Patrick A Ott, Matthew D Hellmann, et al.
Kidney International|June 11, 2016
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsFrank B Cortazar, Kristen A Marrone, Megan L Troxell, et al.
Cancer|April 23, 2020
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 studyJanice M Mehnert, Emily Bergsland, Bert H O'Neil, et al.
Clinical Epigenetics|July 30, 2015
Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomasJonathan J Lee, Lynette M Sholl, Neal I Lindeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell CarcinomaKent W Mouw, James M Cleary, Brendan Reardon, et al.
Cancer|January 29, 2019
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanomaPatrick A Ott, Anna C Pavlick, Douglas B Johnson, et al.
Pageof 67